Eikon Therapeutics

Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO February 4, 2026 News Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end Eikon Therapeutics, a Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers,... Read more